A series of synthetic nicotinamide cofactors were synthesized to replace natural nicotinamide cofactors and promote enoate reductase (ER)-catalyzed reactions without compromising activity or stereoselectivity of the bioreduction process. Conversions and enantioselectivities of up to >99% were obtained for C=C bioreductions and the process was successfully upscaled. Furthermore, high chemoselectivity was observed when employing these nicotinamide cofactor mimics (mNADs) with crude extracts in ER-catalyzed reactions.
The rapidly expanding scope of ER-catalyzed stereospecific reductions makes this method a viable alternative to transition metal-catalyzed reductions. New ERs are constantly added to the toolbox from natural sources 1d,2 and obtained via protein engineering. 3 These enzymes are en route to becoming truly practical catalysts, although one remaining challenge involves their dependency on reduced nicotinamide cofactors [NAD(P)H] providing the reducing equivalents needed for the alkene bioreduction. NAD(P)H is rather expensive, 4 forbidding its stoichiometric use at high scale. In principle, this can be overcome by using an (enzymatic) cofactor regeneration system.
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Another challenge resulting from the NAD(P)Hdependency of ERs arises with conjugated aldehydes and ketones as starting materials. Here, frequently unsatisfactory chemoselectivity is observed unless highly purified, alcohol dehydrogenase (ADH)-free, enzyme preparations are used. The reason thereof lies in the overlap of the substrate scope for both enzyme classes. As a result, both substrates and products of the ER-catalyzed transformation can also be converted by 'contaminating' ADHs leading to complex product mixtures, impairing the overall chemoselectivity of the reactions. 1b,6 Substitution of NAD(P)H as a reducing agent by other reductants appears to be straightforward with ERs and may be the method of choice to circumvent the abovementioned challenges. Indeed, some promising approaches for NAD(P)H-independent regeneration have been reported recently.5 a,7
We became interested in synthetic, functional mimics of the natural nicotinamide cofactors (mNAD, Scheme 1) as stoichiometric reductants to promote ER-catalyzed reduction reactions. Scheme 1. Asymmetric bioreduction of conjugated C=C double bonds using synthetic nicotinamide mimics (1-5)a and 6
These mNADs are simple and cheap to synthesize, starting from commercially available pyridine derivatives (1,3-5)c; thus, the nitrogen was alkylated with benzyl or n-butyl bromide under reflux to obtain the bromide salts (1-5)b in high yields (81-92%), and the pyridinium ring was reduced into the corresponding dihydropyridine (1-5)a in moderate to high yields (35-81%) with sodium dithionite and sodium bicarbonate (Scheme 2).
Scheme 2.
Straightforward two-step synthesis of the reduced nicotinamide mimics mNADs (1-5)a Synthetic mNADs have received considerable attention as cost-efficient alternatives to the natural NAD(P)H cofactors.
8 Unfortunately, the catalytic efficiencies of the wild-type alcohol dehydrogenases with mNADs generally fall back by orders of magnitude below their activity with the natural cofactors. 9 In that respect, ERs represent an exception as they exhibit significant 'cofactor promiscuity'.
7a-c In a first set of experiments, we evaluated the scope of enzymes accepting the mNAD 1a as a replacement for NAD(P)H. As a model reaction, we chose the reduction of ketoisophorone (7a) to the corresponding levodione product (7b) to assess the conversion as well as the enantioselectivity of the ERcatalyzed reaction (Table 1) . We were pleased to find that 1a could replace the natural cofactors with a range of ERs without impairing the final yield or enantiospecificity of the reaction (entries 1-9). It is worth mentioning here that in the absence of either cofactor or enzyme no conversion was detectable within the time frame of the experiments. For further investigations the enoate reductase homologue from Thermus scotoductus (TsER) was used.
11 As shown in Table 2 , a broad range of different enones (entries 1-8), enals (entries 9-12) and maleimides (entries 13-16) could be converted in excellent yield and enantiospecificity demonstrating the preparative broadness of the 'mimic-approach'. Currently, we are bringing the proposed bioreduction scheme to preparative scale. A first gram-scale reduction of N-phenyl-2-methyl maleimide (500 mM) gave excellent conversion and optical purities of the product (>99%) and acceptable isolated yields (>70%), showing the synthetic usefulness of this C=C reduction process to obtain enantioenriched compounds on a high scale.
In order to obtain a more detailed insight into the reduction performance, the mNADs (1-5)a and 6 were evaluated and compared to the natural cofactors (NADH and NADPH). (5a) and the Hantzsch ester (6), all synthetic nicotinamides exhibited equal or better activity with TsER. For example, initial rates obtained with 2a were 1.5-fold higher than with NADPH and almost double than with NADH. It is worth mentioning that the enantioselectivity in all cases was exclusive. The observed high activity of mimics (1-4)a, even exceeding the activity of the natural cofactors, was somewhat unexpected, as with other enzyme classes investigated so far a significant decrease in activity had been observed. Molecular docking simulations of TsER with the mimics (Figure 2 ) confirmed the existence of productive binding modes for mimics 1a to 5a, leading to the reduced catalytically active FMNH 2 species.
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Interestingly, for the Hantzsch ester (6) only unproductive binding was observed, supporting the experimental observations. Possibly, the increased activity with mimics can be explained by an increased FMN-reduction rate. Finally, we investigated the presumed chemoselectivity advantage of using NADH mimics over natural cofactors. For this, the product distribution in the reduction of citral (15) was compared using crude preparations of YqjM, recombinantly expressed in Escherichia coli. As shown in Table 3 , using 1a as a reductant, the desired C=C double bond reduction product (citronellal, 16) was obtained as the sole product, while with NADH significant amounts of carbonyl reduction products (citronellol 18 and geraniol 17) were formed.
Overall, we have demonstrated that cheap synthetic analogues of the natural nicotinamide cofactors (mNADs) represent a true alternative to the established regeneration systems to promote ER-catalyzed reduction reactions and apply them to preparative scale. Already under nonoptimized conditions, equal or higher conversions have (12) Although at this stage we cannot entirely exclude a mechanism wherein FMN is reduced in solution and then binds to the apo-ER.
been obtained compared to those with the natural cofactors, without altering the selectivity. Another very interesting opportunity with mNADs lies in the bioorthogonality 13 of these reduction schemes. The very poor activity of most enzyme classes tested so far with mNADs (particularly alcohol dehydrogenases and monooxygenases) enable the use of poorly purified (and hence cheap) ER preparations without impairing the selectivity of the desired reactions. Admittedly, issues such as the in situ regeneration of catalytic amounts of mNADs and/or recycling will have to be addressed in order to fully exploit their catalytic potential. Also, more mechanistic and kinetic studies as well as further modeling will be necessary to understand the catalytic mechanism. These studies are currently underway in our laboratories, eventually leading to a truly practical approach for White Biotechnology.
